Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: Dual versus monotherapy with bronchodilators in GOLD group B COPD patients according to baseline FEV1 level: a patient-level pooled analysis of phase-3 randomized clinical trials

Fig. 2

Difference between dual therapy vs. monotherapy in change from baseline in SGRQ score. CI confidence interval, GOLD Global initiative for Chronic Obstructive Lung Disease, LABA long-acting beta-2 agonist, LAMA long-acting muscarinic antagonist, LSM least squares mean, SGRQ St. George’s Respiratory Questionnaire

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us